Glenmark Pharmaceuticals has entered into a strategic partnership with China-based Hansoh Pharmaceutical to co-develop and commercialize an innovative oncology drug, marking a significant step in its global research-led growth strategy. The collaboration underscores Glenmarkâs focus on strengthening its specialty and innovation portfolio while leveraging international partnerships to accelerate drug development. Under the agreement, Glenmark gains rights to develop and market the cancer therapy in select territories, while Hansoh retains manufacturing and development responsibilities.